FectoVIR®-LV Transfection Reagent
Transfection Reagent, 1ml/Unit
Transfection Reagent, 100ml/Unit
Transfection Reagent, 10ml/Unit
- Productivity: Reach highest Lentiviral vectors titers in suspension systems
- Cost-effectiveness: Reduce your cost per batch with high titers and low DNA consumption
- Scalability: Produce at large scale with low complexation volume and long complex stability
- Time saving: Use Polyplus DOE service to optimize your process in a record time
| Storage Condition | 6 °C ± 3°C |
| Shelf Life | 19 Months |
| Sterile | Yes |
| Cell Specific | HEK-293 and derivatives |
| Bioproduction | Yes |
| DNA | Yes |
| Virus Production | Yes |
Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs.
Powered by Bioz